Physician profile
Scott Rahimi
NPI 1093939118
$39,158.66
in general payments reported to CMS, 2019-2025
35 companies · $33K in 2025
The $33K reported for 2025 was more than what 93% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,671 · 2020: $68.63 · 2021: $1,084 · 2022: $402 · 2023: $502 · 2024: $606 · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,105.00 |
| Food and Beverage | $1,827.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collagen Matrix, INC | $32,105.00 | 2025 | |
| Innovasis INC | $2,514.77 | 2019 | |
| Microvention, INC. | $1,208.56 | 2019-2024 | Stent, Sofia 6f-131cm Str |
| Silk Road Medical, INC. | $768.29 | 2021 | |
| Medtronic, INC. | $561.86 | 2021-2025 | Strata, Mazor X System, Linq II |
| Imperative Care, INC | $234.74 | 2023-2025 | Zoom 88-T Large Distal Platform |
| Depuy Synthes Sales INC. | $230.53 | 2019-2025 | Cerenovus Enterprise |
| Stryker Corporation | $188.90 | 2020-2023 | Trevo, Synchro Select, Axs Vecta 71 |
| Zap Surgical Systems, INC. | $163.18 | 2025 | Zap-X Mv Imager, Zap-X Treatment Planning Software, Zap-X Radiosurgery System |
| Route 92 Medical, INC. | $131.92 | 2024 | 8f Base Camp Sheath System |
| Nuvasive, INC. | $96.25 | 2022 | |
| Leica Microsystems INC. | $91.16 | 2025 | |
| Pfizer INC. | $85.67 | 2019-2024 | |
| Aesculap, INC. | $82.14 | 2021 | |
| Boston Scientific Corporation | $75.28 | 2020-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mindray Ds USA, INC. | $74.24 | 2022 | |
| Orthofix Medical, INC. | $60.29 | 2019 | |
| Omniscient Neurotechnology America LTD | $52.00 | 2021 | |
| Amgen INC. | $48.86 | 2022 | |
| Integra Lifesciences Corporation | $48.74 | 2019-2024 | Codman Certas, Cusa Clarity, Codman Hakim |
| Kyocera Medical Technologies, INC. | $36.42 | 2025 | |
| Medtronic USA, INC. | $34.88 | 2019-2020 | |
| Lemaitre Vascular, INC. | $34.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.21 | 2022-2023 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $27.33 | 2022 | |
| Biogen, INC. | $27.25 | 2023 | Skyclarys |
| Baxter Healthcare | $24.15 | 2023 | Floseal |
| Qapel Medical INC | $22.78 | 2025 | |
| Kuros Biosciences USA, INC | $21.89 | 2023 | |
| Zimmer Biomet Holdings, INC. | $18.96 | 2025 | Thinflap |
| Janssen Pharmaceuticals, INC | $15.72 | 2020 | |
| Flowonix Medical Incorporated | $14.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.01 | 2019 | |
| Irras USA, INC. | $11.83 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,745.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Rahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.